With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...

Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...

DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management ...

DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions ...

DUBLIN – Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its ...

Trinity Biotech plc announced a significant step in its transformation plan by appointing Barclays Capital Inc. as its exclusive financial advisor. The company is shifting its focus to developing ...

The stock has a market cap of $12.48 million, a PE ratio of -0.31 and a beta of 1.20. Trinity Biotech has a twelve month low of $0.63 and a twelve month high of $3.55. An institutional investor ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a continuous glucose monitor (CGM) to market. Dublin, Ireland-based Trinity Biotech ...